Given the Royalty Rate of 19.0% is significantly higher than the typical 6.0-7.0% range, what justifies this premium royalty structure and how does it compare to competitors in the infusion services sector?
#1
The monthly Technology Fee of $1,500 is substantially above the typical $165-$427.50 range. What specific technology services and systems does this fee cover, and what is the franchisor's upgrade schedule for these systems?
#2
With a Transfer Fee of $100,000 (typical range $7,500-$20,000), how many transfer requests have been denied or requested price reductions over the past 3 years, and on what grounds?
#3
The 3-year turnover rate of 18.9% exceeds the typical 0.0-12.33% range. What were the primary reasons franchisees exited in 2019 and 2021 when closures peaked at 7 and 8 units respectively?
#4
Item 19 financial performance data shows high variance with top quartile sales of $38.5 million versus bottom quartile of $921,785. What specific factors drive this performance disparity among franchisees?
#5
The contract lists 25 non-curable defaults versus only 3 curable defaults. Can you provide the full list of non-curable defaults and examples of how they have been applied in termination cases?
#6
What specific refurbishment requirements and costs are mandated as renewal conditions for the two 10-year renewal periods?
#7
The 10-day cure period for non-payment defaults is stated in the termination clause. What is the franchisor's practice regarding late fees and 18% annual interest, and are these typically waived for first-time violations?
#8
The minimum gross revenue requirement of $500,000 during the first full year is mentioned in the financial obligations section. What percentage of franchisees failed to meet this threshold in their first year, and what were the consequences?
#9
Territory is protected but not exclusive. Can the franchisor open competing Vital Care locations within the protected territory if they deem it necessary, and under what circumstances would this occur?
#10
With 8 categories of supplier restrictions, which suppliers are franchisor-approved for the key products and services, and does the franchisor receive rebates or revenue sharing from these approved suppliers?
#11
The agreement allows the franchisor to control pricing for essential products if a supplier is discontinued. How often has pricing control been exercised, and by what percentage have franchisees been required to increase patient costs?
#12
What support and training do franchisees receive during the initial ramp-up period to achieve the $500,000 minimum revenue requirement in year one?
#13
The non-compete clause specifies 2 years and 10 miles. Does this apply only to healthcare service businesses, or does it extend to all franchise concepts?
#14
Given the $60,000 Franchise Fee exceeds the typical range, what is included in initial training, site selection assistance, and pre-opening support compared to competitors?
#15
How has the franchisor handled the closure and ceased operations units from 2019-2023, particularly the 7 closures in 2019? Were there any franchisor-initiated terminations during this period?
#16
The renewal fee is stated as 15% of the then-current franchise fee. If the franchise fee increases to $80,000 by year 10, would the renewal fee be $12,000, and is this amount disclosed in advance?
#17
With zero litigation cases over 3 years, have there been any disputes, complaints to state regulators, or arbitration proceedings not reflected in formal litigation?
#18
The system has grown from 53 to 76 units in 3 years. What is the franchisor's target unit growth rate, and what franchisee recruitment strategies are being employed?
#19
Support & Training score of 79 falls below the typical range of 81.0-96.25%. What specific training gaps or limitations exist compared to other franchisors in healthcare services?
#20